Aimmune Therapeutics (AIMT) Sees IPO Pricing of $14 - $16/Share

Aimmune Therapeutics, Inc. (Nasdaq: AIMT) filed an amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to sell 8,333,333 shares and sees an offering price of $14 to $16 per share. The company plans to list on the Nasdaq under the ticker AIMT.

The offering is being made via BofA Merrill Lynch, Credit Suisse, and Piper Jaffray.

Aimmune Therapeutics is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies.

Aimmune continued, . It is estimated that over 30 million people in the United States and Europe have a food allergy, with peanut allergy being the most prevalent and most commonly associated with severe outcomes and life-threatening events. Our therapeutic approach, which we refer to as Characterized Oral Desensitization Immunotherapy, or CODIT, is a system designed to desensitize patients to food allergens using rigorously characterized biologic products, defined treatment protocols and tailored support services. In ARC001, our recently completed Phase 2 study of our lead CODIT product candidate, AR101, all of the 23 patients who completed the AR101 treatment regimen were desensitized to a clinically meaningful level of peanut protein of at least 443 mg, a level that substantially exceeds the amount of peanut protein typically encountered in an accidental exposure, which we believe to be approximately 100 mg or less. We intend to initiate a Phase 3 registration trial of AR101 in early 2016 and Phase 2 studies of other CODIT product candidates for two additional food allergies in 2016. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation by the U.S. Food and Drug Administration, or FDA, and, if our planned Phase 3 trial is successful, we intend to file a Biologics License Application with the FDA and a Marketing Authorization Application with the European Medicines Agency. We have worldwide commercial rights to all of our product candidates and, if approved, intend to commercialize in the United States and Europe with our own specialty sales force.

You May Also Be Interested In

• DeFi Development Corp. plans $20M preferred stock offering
• Yum! Brands completes Pizza Hut sale to LongRange for $1.5B
• Figure Technology Solutions completes acquisition of Kiavi